Cephalon’s Nuvigil Filing Remains On Schedule For First Quarter

Cephalon's modafinil follow-on Nuvigil (armodafinil) showed statistical significance in each of four pivotal studies intended to support a first-quarter NDA filing, the firm announced Feb. 10